| U.S. Food and Drug Administration Approves New Formulations of Viread® for Use ... - Business Wire (press release) |
|
|
Business Wire (press release) Monitor CrCl and serum phosphorus in patients at risk, including those who have previously experienced renal events while receiving Hepsera ® (adefovir dipivoxil). Avoid administering Viread with concurrent or recent use of nephrotoxic drugs. |